<DOC>
	<DOCNO>NCT02599402</DOCNO>
	<brief_summary>The purpose study determine effect combination treatment Nivolumab Ipilimumab follow Nivolumab monotherapy patient previously untreated advanced Melanoma .</brief_summary>
	<brief_title>Nivolumab Combined With Ipilimumab Followed Nivolumab Monotherapy First-Line Treatment Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Potential subject must advance Melanoma ( stage III IV confirm biopsy ) spread sit body unable remove surgery Potential subject must newly diagnose advanced Melanoma receive treatment advanced disease The subject receive previous primary treatment additional treatment ( give primary treatment ) permit complete least 6 week prior study entry side effect treatment resolve If subject receive follow primary treatment previously ; permit enrol study ( antiCTLA4 , antiPD1 , antiPDL1 , antiPDL2 , drug specifically target Tcell costimulation checkpoint pathway antiCD137 ) Potential subject ( disease spread brain ) previously receive primary treatment permit evidence disease confirm MRI ( least 2 week primary treatment complete 6 week first dose study drug ) Potential subject must receive intravenous steroid treatment ( &gt; 10 mg/day ) intravenously least 2 week prior study drug administration . There current ( previously treat ) disease spread brain Subjects receive prior therapy antiCTLA4 , antiPD1 , anti PDL1 antiPDL2 , antiCD137 agent ( antibody drug specifically target Tcell costimulation checkpoint pathway ) adjuvant , neoadjuvant , advanced melanoma treatment part clinical trial Subjects autoimmune disease . Subjects Type I diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment , condition expect recur absence external trigger permit enroll All side effect previous primary treatment alopecia , fatigue , peripheral neuropathy must resolve Grade 1 baseline administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>